November 21, 2026

What India's New CDSCO SUGAM Query Response Mechanism Means for Drug Manufacturers, Medical Device Companies, IVD Manufacturers and Importers

The Central Drugs Standard Control Organization (CDSCO) has introduced a structured reminder and rejection mechanism for long-pending regulatory applications submitted through the SUGAM online portal. Announced through a public notice dated 16 January 2026, the initiative aims to address the backlog of applications awaiting responses to regulatory queries.

Under the mechanism, applicants receive three reminders at prescribed intervals to respond to outstanding queries. If the applicant fails to submit the required response even after these reminders, CDSCO issues a fourth and final communication declaring the application rejected, with the applicable statutory fee forfeited.

The reminder schedule establishes a 90-day period between the first reminder and the final disposal notice, with subsequent reminders issued at 30-day intervals.

The measure covers applications across several CDSCO divisions, including New Drugs, Investigational New Drugs, Subsequent New Drugs, Fixed Dose Combinations, Import, Cosmetics, Biologics, Medical Devices and In Vitro Diagnostics (IVDs), subject to the application categories and timelines specified in the notice.

For companies operating in India's pharmaceutical and medical technology sectors, this development makes timely query management, regulatory correspondence monitoring and submission tracking increasingly important.

Manufacturers, importers, authorized representatives and regulatory affairs teams should review their pending SUGAM applications and establish internal alert systems to avoid missed deadlines, application rejection and potential financial losses.

Why the CDSCO SUGAM 90-Day Rule Matters

Regulatory applications frequently require additional information, technical clarification, revised documents or supporting evidence during the CDSCO evaluation process.

When applicants fail to respond to these queries, applications may remain pending for extended periods, creating administrative backlogs and delaying regulatory decisions.

CDSCO's January 2026 initiative introduces a structured reminder mechanism to encourage applicants to address outstanding queries within defined timelines.

The development is particularly important because non-response can lead to:

  • Rejection of pending regulatory applications.
  • Forfeiture of applicable statutory application fees.
  • Additional expenses associated with fresh applications.
  • Delays in product approvals and market entry.
  • Disruption to manufacturing and import planning.
  • Increased regulatory workload for compliance teams.

Companies should therefore treat every SUGAM query as a time-sensitive regulatory action rather than routine portal correspondence.

What Is the CDSCO SUGAM 90-Day Auto-Rejection Rule?

The SUGAM portal is an electronic regulatory submission platform operated by CDSCO under the Ministry of Health and Family Welfare.

It facilitates online applications for various regulatory activities, including drug approvals, import permissions, biological product submissions, medical device applications and clinical trial-related processes.

Through its public notice dated 16 January 2026 (File No. IT-11011(11)/1/2026), CDSCO introduced a structured reminder process for applications awaiting responses to regulatory queries.

The mechanism provides three reminders followed by a fourth and final disposal communication.

Failure to respond through email and the SUGAM portal after the prescribed reminder process can result in rejection and fee forfeiture.

Key Regulatory Details

Regulatory Element

Details

Regulatory Authority

Central Drugs Standard Control Organization (CDSCO)

Announcement Date

16 January 2026

Reference Number

IT-11011(11)/1/2026

Regulatory Platform

SUGAM Online Portal

Reminder Mechanism

Three reminders followed by a final disposal notice

Reminder Interval

30 days between successive reminders

Final Consequence

Application rejection and applicable fee forfeiture

Primary Objective

Disposal of long-pending applications and reduction of regulatory backlog

CDSCO SUGAM Reminder Timeline: Understanding the 90-Day Mechanism

The most important aspect of the new mechanism is the sequence of reminders and the time available to applicants to respond.

According to the annexure accompanying the CDSCO notice, the reminder process follows a 30-day interval between each communication.

Reminder and Rejection Timeline

Stage

Timeline

Regulatory Action

First Reminder

Initial reminder

CDSCO issues a customized reminder for the pending application

Second Reminder

30 days after the first reminder

Applicant receives another reminder to submit the pending response

Third Reminder

30 days after the second reminder

Final reminder is issued

Fourth Communication

30 days after the third reminder

Disposal notice communicates application rejection and fee forfeiture

 

Important: The 90-day period is calculated from the first reminder to the fourth disposal communication under the prescribed schedule. It is not necessarily calculated from the original application submission date or the date of the first regulatory query.

The January 2026 notice also specifically addressed applications that had remained pending with applicants for more than two years and had already undergone the three-reminder process. These applications were notified for rejection after 30 days from the date of the public notice.

Companies should distinguish this backlog-clearing action from the structured reminder mechanism for other pending applications.

Which Regulatory Applications Are Covered?

The January 2026 public notice identifies several CDSCO divisions whose applications were affected by the backlog-clearance initiative.

The notice specifically refers to applications in the following categories:

Product / Application Category

Regulatory Coverage

Key Compliance Consideration

New Drugs

New drug applications

Respond to technical and regulatory queries

Investigational New Drugs

Investigational drug submissions

Maintain complete clinical and technical documentation

Subsequent New Drugs

Subsequent new drug applications

Address outstanding evaluation requirements

Fixed Dose Combinations

FDC applications

Provide required formulation and supporting information

Import Applications

Drug import-related submissions

Monitor pending import permission and registration queries

Biologics

Applications pending since 2016

Review outstanding regulatory correspondence

Medical Devices

Applications pending since 2018

Address technical, safety and documentation queries

In Vitro Diagnostics

IVD applications pending since 2018

Respond to performance and regulatory assessment queries

Cosmetics

Cosmetic-related applications

Track pending submissions and regulatory clarifications

The application-age references above reflect the historical backlog categories identified in the notice. Companies should verify the specific applicability and timelines for each application rather than assuming that every newly filed application is subject to an identical backlog-disposal action.

What Happens If an Applicant Misses the 90-Day Deadline?

Failure to respond to regulatory queries within the prescribed reminder process can have significant consequences.

1. Automatic Application Disposal and Rejection

If the applicant does not respond to outstanding queries even after three reminders, CDSCO issues a fourth and final communication informing the applicant that the application stands rejected.

This can affect product approval plans, regulatory submissions and market-entry timelines.

2. Forfeiture of Statutory Fees

The public notice states that the application fee will be forfeited in accordance with applicable provisions.

Companies may therefore face financial losses in addition to regulatory delays.

3. Fresh Application Requirements

Following rejection, businesses may need to prepare and submit a fresh application, depending on the applicable regulatory pathway and requirements.

This may involve:

  • Preparing a new application dossier.
  • Rechecking technical and administrative documents.
  • Addressing the original regulatory deficiencies.
  • Completing applicable fee payments.
  • Reinitiating the regulatory review process.

4. Delayed Product Launches and Market Entry

Rejection can disrupt commercial plans, particularly where product launches depend on import permissions, manufacturing approvals or regulatory clearances.

5. Additional Regulatory Workload

Regulatory affairs teams may need to repeat documentation reviews, coordinate with technical departments and obtain updated supporting information.

What Manufacturers and Importers Should Do Now

Companies submitting regulatory applications through SUGAM should establish a structured query-monitoring and response management system.

Recommended compliance actions include:

  • Monitor the SUGAM dashboard daily.
  • Check registered email accounts for CDSCO correspondence.
  • Review spam and junk folders to identify missed reminders.
  • Maintain a central register of pending applications.
  • Record the date of the first reminder for every application.
  • Assign responsibility for responding to each query.
  • Coordinate with quality, manufacturing, clinical and technical teams.
  • Submit complete responses within the prescribed timeline.
  • Maintain copies of submitted responses and supporting documents.
  • Verify that responses have been successfully uploaded through SUGAM.

Businesses should not wait until the final reminder to initiate corrective action.

SUGAM Application Compliance Readiness Checklist

Assessment Area

Recommended Action

Compliance Objective

Application Inventory

Identify all pending SUGAM applications

Establish submission visibility

Dashboard Monitoring

Check application status daily

Prevent missed queries

Email Monitoring

Review inbox, spam and junk folders

Identify regulatory communications

Reminder Tracking

Record first, second and third reminder dates

Monitor the 90-day timeline

Query Management

Assign responsible personnel

Ensure timely responses

Technical Documentation

Prepare supporting evidence and revised documents

Address CDSCO observations

Response Submission

Upload complete replies through SUGAM

Maintain regulatory correspondence

Submission Verification

Confirm successful upload and retain acknowledgement

Establish an audit trail

Escalation Process

Notify regulatory management of approaching deadlines

Reduce rejection risks

Automated Alerts

Configure internal email reminders

Strengthen deadline management

Impact on Pharmaceutical, Medical Device and IVD Businesses

The new mechanism makes regulatory correspondence management an important part of product compliance and market access planning.

1. Pharmaceutical manufacturers should review pending drug applications, formulation-related queries, clinical documentation and technical responses.

2. Medical device manufacturers should ensure that technical documentation, product specifications, safety information and supporting evidence are readily available.

3. IVD manufacturers should pay attention to performance evaluation information, analytical validation documents and other regulatory clarifications.

4. Importers and authorized representatives should coordinate with overseas manufacturers to obtain missing documents and respond to CDSCO queries within the prescribed timeline.

For multinational companies, effective communication between Indian regulatory teams and international headquarters is particularly important.

How Automated Alerts Can Strengthen SUGAM Compliance

Manual monitoring of regulatory portals and email correspondence can increase the possibility of missed deadlines, particularly when companies manage multiple applications simultaneously.

An internal automated alert mechanism can help regulatory teams track upcoming response deadlines.

A practical alert programme may include:

  • An initial notification when a CDSCO query is received.
  • A reminder when the first regulatory reminder is identified.
  • Additional alerts before the second and third reminder stages.
  • An escalation notification to the regulatory manager.
  • A final deadline alert before the disposal communication.

Companies can also configure up to four internal email notifications to support application monitoring.

However, these internal alerts are company-managed controls, not additional reminders guaranteed by CDSCO. Applicants should not wait for the final alert before submitting their responses.

Frequently Asked Questions

1. What is the CDSCO SUGAM 90-day auto-rejection rule?

It is a structured reminder and disposal mechanism under CDSCO's 16 January 2026 public notice. Applicants receive three reminders at 30-day intervals, followed by a final disposal communication if queries remain unanswered.

2. When was the CDSCO SUGAM rejection mechanism announced?

CDSCO issued the relevant public notice on 16 January 2026 under File No. IT-11011(11)/1/2026.

3. When does the 90-day period start?

Under the structured reminder schedule, the period runs from the first reminder to the fourth disposal notice, with each subsequent communication scheduled 30 days apart.

4. Does the rule apply to drugs, medical devices and IVDs?

Yes. The notice identifies applications across drug-related divisions, medical devices and IVDs, among other categories. The specific application scope and historical backlog timelines should be checked against the notice.

5. What happens after three unanswered reminders?

CDSCO issues a fourth and final communication informing the applicant that the application stands rejected, with applicable fees forfeited.

6. Will the application fee be refunded after rejection?

The notice provides for forfeiture of the application fee in accordance with applicable provisions.

7. Can an applicant submit a fresh application after rejection?

A fresh application may be necessary, subject to the applicable regulatory pathway and submission requirements. The applicant should address the original deficiencies before resubmission.

8. Does the deadline start from the last reminder?

No. The 90-day reminder sequence starts with the first reminder. Each subsequent reminder is scheduled 30 days after the preceding reminder.

9. Should companies monitor the SUGAM portal daily?

Yes. Daily monitoring, combined with registered email and spam-folder checks, is a practical way to identify queries and prevent missed regulatory communications.

10. How can companies prevent SUGAM application rejection?

Companies should maintain an application tracker, configure internal alerts, assign query-response responsibilities and submit complete responses within the prescribed timelines.

Conclusion

CDSCO's January 2026 SUGAM public notice introduces a structured approach to managing long-pending regulatory applications awaiting query responses.

The three-reminder mechanism, followed by a final disposal communication, makes timely regulatory correspondence management essential for pharmaceutical manufacturers, medical device companies, IVD manufacturers and importers.

With application rejection and statutory fee forfeiture as potential consequences, businesses should strengthen their SUGAM monitoring procedures, establish internal escalation systems and ensure that regulatory queries receive timely attention.

Companies should priorities daily dashboard monitoring, email tracking, accurate reminder-date recording and complete query responses to reduce regulatory delays and protect their product approval timelines.

A proactive regulatory affairs strategy can help businesses manage CDSCO submissions more efficiently and maintain continuity in India's pharmaceutical and medical device markets.

How Maven Regulatory Solutions Can Help

Maven Regulatory Solutions supports pharmaceutical, medical device and IVD companies with:

  • CDSCO regulatory compliance assessments.
  • SUGAM application monitoring support.
  • Regulatory query response coordination.
  • Drug registration and approval support.
  • Medical device regulatory assessments.
  • IVD registration and compliance support.
  • Regulatory dossier preparation and review.
  • Technical documentation assessments.
  • Regulatory submission gap assessments.
  • Application status and deadline tracking.
  • Regulatory correspondence management.
  • Compliance documentation and audit support.
  • Indian regulatory intelligence.
  • Product lifecycle regulatory support.

Our approach helps manufacturers, importers and regulatory teams strengthen submission management, address regulatory queries and maintain effective compliance processes aligned with evolving CDSCO requirements.